Eckert & Ziegler stock rises 4.31% since prior report
Published on 11/04/2026 at 18:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAc-225 milestone and stock momentum
- GMP authorization supports clinical supply of Actinium-225 through Eckert & Ziegler's wholly owned subsidiary.
- Production links radium-226 irradiation in the Czech Republic with processing in Braunschweig.
- A commercial-scale Ac-225 facility in China is planned after initial operations expected in early 2027.
Eckert & Ziegler stock rises 4.31% since the previous report
Eckert & Ziegler stock traded at 14.03 euros on Lang & Schwarz at 18:02 CET on Wednesday, November 4, 2026, 0.21 percent above the Xetra close of Wednesday, November 4. The real-time quote of Eckert & Ziegler stock provides the latest market reference.
What has changed since the last report
The latest quote compares with 13.45 euros at 18:07 CET on Tuesday, November 3, cited in the previous report. The increase of 4.31 percent clears the more-than-1.00-percent threshold for a separate second main values edition and is distinct from the same-day Xetra comparison.
GMP approval supports supply
On October 28, 2026, Eckert & Ziegler Therapeutics GmbH received manufacturing authorization for Actinium-225 from the competent German authority. The EQS News release said the certification confirms compliance with Good Manufacturing Practice requirements and facilitates investigational patient treatment.
The production route starts with cyclotron-based irradiation of radium-226 at the Czech Academy of Sciences' Nuclear Physics Institute in the Czech Republic. The irradiated material is then processed at Eckert & Ziegler's Braunschweig site to obtain GMP-grade Ac-225.
Capacity plans extend to China
The group's Qi Kang Medical Technology joint venture in Jintan, China, is preparing a commercial-scale Ac-225 production site. Initial operations are expected in early 2027, with a second phase planned afterward. The approval strengthens the supply platform, while its financial contribution will depend on production volumes, customer programs and commercial adoption.
Eckert & Ziegler at a glance
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- Ticker: EUZ.DE
- Lang & Schwarz quote: 14.03 euros at 18:02 CET on November 4, 2026
- Change since previous report: 4.31 percent above 13.45 euros at 18:07 CET on November 3, 2026
- Xetra close: 14.00 euros on November 4, 2026
- Index: TecDAX
Investors can follow the broader German market through the DAX.
